CD4+ T cell responses in patients with chronic hepatitis C undergoing peginterferon/ribavirin therapy correlate with faster, but not sustained, viral clearance

被引:16
作者
Aberle, Judith H.
Perstinger, Gabriela
Weseslindtner, Lukas
Sinzinger, Ursula
Gurguta, Calin
Steindl-Munda, Petra
Kundi, Michael
Popow-Kraupp, Theresia
Ferenci, Peter
Holzmann, Heidemarie
机构
[1] Med Univ Vienna, Inst Virol, A-1095 Vienna, Austria
[2] Med Univ Vienna, Dept Internal Med Gastroenterol & Hepatol, A-1095 Vienna, Austria
[3] Med Univ Vienna, Inst Environm Hlth, A-1095 Vienna, Austria
关键词
D O I
10.1086/513278
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
T cell immune responses may be important for the elimination of chronic hepatitis C virus (HCV) infection during antiviral treatment. In the present study, the kinetics of T cell responses to HCV antigens (NS3-4 and core) were prospectively assessed and were correlated with virologic outcome in 31 patients with chronic HCV infection undergoing peginterferon-alpha 2a/ribavirin therapy. NS3-4-directed T helper cell type 1 (Th1) responses were detected in 77% of patients with a significant decline in viremia at treatment week 4 but were not detected not in those with a slower viral decline. The detectability of NS3-4-directed Th1 responses was associated with faster viremia clearance, was short-lived, and did not seem to be associated with the final treatment outcome.
引用
收藏
页码:1315 / 1319
页数:5
相关论文
共 16 条
[1]   Prospective study of viral clearance and CD4+ T-cell response in acute hepatitis C primary infection and reinfection [J].
Aberle, JH ;
Formann, E ;
Steindl-Munda, P ;
Weseslindtner, L ;
Gurguta, C ;
Perstinger, G ;
Grilnberger, E ;
Laferl, H ;
Dienes, HP ;
Popow-Kraupp, T ;
Ferenci, P ;
Holzmann, H .
JOURNAL OF CLINICAL VIROLOGY, 2006, 36 (01) :24-31
[2]   The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection [J].
Barnes, E ;
Harcourt, G ;
Brown, D ;
Lucas, M ;
Phillips, R ;
Dusheiko, G ;
Klenerman, P .
HEPATOLOGY, 2002, 36 (03) :743-754
[3]   Further reduction of ribavirin dose in HCV genotype 2/3 patients receiving peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®):: Interim results of a randomised controlled trial [J].
Ferenci, P. ;
Brunner, H. ;
Laferl, H. ;
Bergholz, U. ;
Rosenbeiger, M. ;
Stauber, R. ;
Maieron, A. ;
Fischer, G. ;
Bischof, M. ;
Steindl-Munda, P. .
JOURNAL OF HEPATOLOGY, 2006, 44 :S37-S37
[4]   Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin [J].
Ferenci, P ;
Fried, MW ;
Shiffman, ML ;
Smith, CI ;
Marinos, G ;
Gonçales, FL ;
Häussinger, D ;
Diago, M ;
Carosi, G ;
Dhumeaux, D ;
Craxì, A ;
Chaneac, M ;
Reddy, KR .
JOURNAL OF HEPATOLOGY, 2005, 43 (03) :425-433
[5]  
Ferenci R, 2006, J HEPATOL, V44, pS6
[6]   Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose [J].
Hadziyannis, SJ ;
Sette, H ;
Morgan, TR ;
Balan, V ;
Diago, M ;
Marcellin, P ;
Ramadori, G ;
Bodenheimer, H ;
Bernstein, D ;
Rizzetto, M ;
Zeuzem, S ;
Pockros, PJ ;
Lin, A ;
Ackrill, AM .
ANNALS OF INTERNAL MEDICINE, 2004, 140 (05) :346-355
[7]  
Herrmann E, 2000, ANTIVIR THER, V5, P85
[8]  
Hultgren C, 2004, J HEPATOL, V40, P971, DOI [10.1016/j.jhep.2004.02.002, 10.1016/S0168-8278(04)00052-2]
[9]   Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy [J].
Jensen, DM ;
Morgan, TR ;
Marcellin, P ;
Pockros, PJ ;
Reddy, KR ;
Hadziyannis, SJ ;
Ferenci, P ;
Ackrill, AM ;
Willems, B .
HEPATOLOGY, 2006, 43 (05) :954-960
[10]   Peginterferon alone or with ribavirin enhances HCV-specific CD4+ T-helper 1 responses in patients with chronic hepatitis C [J].
Kamal, SM ;
Fehr, J ;
Roesler, B ;
Peters, T ;
Rasenack, JW .
GASTROENTEROLOGY, 2002, 123 (04) :1070-1083